Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Evotec Partner on Protein Biomarkers for Cancer Drugs

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Roche and Evotec today announced a three-year agreement directed at biomarker discovery for use with oncology drugs under development by Roche.

Under the terms of the deal, Evotec will use its PhosphoScout platform for the discovery of protein phosphorylation biomarkers that may be used to determine the efficacy of targeted cancer drugs in patients and for dosing decisions.

The firms will conduct multiple biomarker programs for therapeutic antibodies or small-molecule inhibitors, and Roche will conduct clinical trials and assess the development of companion diagnostics for patient stratification. Evotec will receive undisclosed upfront and milestone payments for each program.

Further details of the deal were not disclosed.

PhosphoScout is a mass spectrometry-based platform for identifying and quantifying cellular phosphorylation events. According to Evotec, it offers unbiased systems-wide profiling of signaling pathways.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.